OMass Therapeutics News and Activities

OMass Therapeutics is owned by Syncona.

Syncona is one of the...

• FTSE 350;
• TOB Iconic 10,000.

Syncona is a company listed under the stock ticker SYNC (GB).

Syncona has a direct presence in 3 countries.

Syncona has 11 subsidiaries including Anaveon, Autolus Therapeutics and Beacon Therapeutics.

They are in:

• Biotechnology83%
• Holding8%
• Other8%

View the org chart displaying its 25 main executives

Most searched biographies at OMass Therapeutics

• Rosamond Deegan, Chief Executive Officer
• Nathalie Franchimont, Director
• Chris Ashton, Non-Executive Director

Create your alert
to follow the executive moves at OMass Therapeutics.

Syncona has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by OMass Therapeutics

• News – Omass
• In The News – Omass

Social media about OMass Therapeutics

• OMass Therapeutics on Wikipedia, Google News & Yahoo Finance
• OMass Therapeutics on LinkedIn, X (Twitter) & YouTube